Antibiotics developer Cempra Pharmaceuticals is one of three healthcare companies expected to go public this week.
A total of eight initial public offerings are expected this week, according to Renaissance Capital, a Greenwich, Connecticut research firm specializing in initial public offerings. Besides Chapel Hill, North Carolina-based Cempra’s planned $86 million IPO, the other healthcare-related IPOs on Renaissance’s radar for this week are Greenway Medical Technologies and Merrimack Pharmaceuticals.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cempra’s two lead drug candidates are antibiotics that would address drug-resistant bacteria. Cempra is targeting an antibiotics market Datamonitor estimates was $19.6 billion in the United States, Japan and the five major European markets in 2009.
Proceeds from the Cempra IPO will finance late-stage clinical trials on two antibiotic candidates targeting drug-resistant bacteria. CEM-101, also called solithromycin, is ready to enter phase 3 clinical trials as a pneumonia treatment. The antibiotic treatment could also have applications in Legionnaires’ disease and sexually transmitted diseases such as syphilis. Cempra reported positive phase 2 clinical trial results for the antibiotic last September, just prior to the firm’s October IPO filing.
A second candidate called Taksta has finished phase 2 clinical trials and would be studied in phase 3 as a treatment for skin infections, including MRSA (Methicillin-resistant Staphylococcus aureus ). Cempra earlier this month updated its filings and set a price range of $11 to $13 per share for the IPO.
Cempra’s IPO is expected to be joined by two other healthcare-related public stock offerings. Georgia health IT firm Greenway Medical Technologies, which provides IT software for ambulatory healthcare providers, expects to raise up to $80 million by selling shares in the $11 to $13 per share range. Merrimack Pharmaceuticals, a Massachusetts firm that has technology to discover and develop novel cancer treatments, plans to raise $173 million by selling shares in the $8 to $10 range.
